Citigroup
CRBU icon

Citigroup’s Caribou Biosciences CRBU Stock Holding History

Citigroup’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,900
Closed -$9.6K – 5855
2024
Q3 		$9.6K Buy
+4,900
New +$10K ﹤0.01% 5293

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citigroup's CRBU Position: Q1 2026 in Review

Citigroup reduced its Caribou Biosciences (CRBU) stake by 24% in Q1 2026, selling an estimated $30.3K and leaving 56,923 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #4254.

Citigroup first reported a position in CRBU in Q3 2021 and has held it in 19 quarters since. The position peaked at $2.41M in Q1 2024. 137 funds tracked by Wall St. Rank hold CRBU as of Q1 2026.

  • Citigroup held 56,923 shares of Caribou Biosciences worth $108K as of Q1 2026.
  • Citigroup sold 17,648 Caribou Biosciences shares in Q1 2026, an estimated $30.3K.
  • Caribou Biosciences made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4254 holding.
  • Citigroup first reported a position in Caribou Biosciences in Q3 2021 and has held it in 19 quarters since.
  • Citigroup's Caribou Biosciences position peaked at $2.41M in Q1 2024.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.